Keryx Biopharma - KERX

doctor NO ha scritto:
"..The FDA indicated that the results of the Phase 2 study and the toxicology studies were adequate to support entry into a Phase 3 program.
Keryx is in the process of finalizing the Phase 3 program in consultation with the FDA. "
Clicca per allargare...


..process of finalizing..
ovvero l'inizio di fase III potebbe più a breve di quanto si possa pensare?
 
..una notizia al giorno..

http://investors.keryx.com/phoenix.zhtml?c=122201&p=irol-newsArticle&ID=1297592&highlight=


Keryx Biopharmaceuticals, Inc. Receives Extension for Nasdaq Listing Compliance
NEW YORK, June 9 /PRNewswire-FirstCall/ --

Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that on June 5, 2009, it received a letter from the NASDAQ Listing Qualifications Hearings Panel granting the Company an extension through August 31, 2009, to regain compliance with Nasdaq Listing Rule 5550(b), which requires the Company to have a minimum of $2,500,000 in stockholders' equity, or $35,000,000 market value of listed securities, or $500,000 of net income from continuing operations for the most recently completed fiscal year or two of the three most recently completed fiscal years, for continued listing on The Nasdaq Capital Market.
The Company expects to be able to comply with Nasdaq Listing Rule 5550(b) for continued listing on The Nasdaq Capital Market by August 31, 2009; however, there can be no assurance that the Company will be able to do so. Failure to comply with the conditions for listing could result in the delisting of the Company's common stock from The Nasdaq Capital Market.
 
You must log in or register to reply here.

Users who are viewing this thread

Total: 1 (members: 0, guests: 1)
Back
Alto